Literature DB >> 12889782

Itraconazole formulation studies of the melt-extrusion process with mixture design.

B Rambali1, G Verreck, L Baert, D L Massart.   

Abstract

Itraconazole is a poorly water soluble compound. One method to increase the aqueous solubility of itraconazole is through formation of a solid dispersion. The purpose of this study is to develop a 40% w/w itraconazole formulation through solid dispersion formation, using hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and hydroxypropylmethyl-cellulose (HPMC) as mixture components. The solid dispersion was obtained by melt-extrusion using a twin-screw corotating melt extruder. A D-optimal mixture design was applied for the development of the optimal itraconazole formulation. The itraconazole fraction varied between 20% w/w and 50% w/w in the mixture design and the HPMC and HP-beta-CD fractions varied between 10% w/w and 60% w/w. The itraconazole formulation was optimized by producing clear extrudates, minimizing the torque, and maximizing the glass transition temperature and the apparent itraconazole solubility in 0.1 N HCl. Regression models were developed for the torque, glass transition temperature, and apparent solubility of itraconazole. High itraconazole fraction in the mixture promoted a better melt processing (minimizes torque). High HPMC fraction (>33% w/w) resulted in clear extrudates, indicating a solid dispersion and resulted in high glass transition temperature of the melt. High HP-beta-CD fraction resulted in increased apparent itraconazole solubility in 0.1 N HCl. The optimal itraconazole formulation consisted of 45% w/w HPMC and 15% HP-beta-CD w/w.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12889782     DOI: 10.1081/ddc-120021313

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  8 in total

1.  Use of Polyvinyl Alcohol as a Solubility Enhancing Polymer for Poorly Water-Soluble Drug Delivery (Part 2).

Authors:  Chris Brough; Dave A Miller; Daniel Ellenberger; Dieter Lubda; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2016-02-10       Impact factor: 3.246

2.  Multicenter comparison of the ISO standard 20776-1 and the serial 2-fold dilution procedures to dilute hydrophilic and hydrophobic antifungal agents for susceptibility testing.

Authors:  Alicia Gomez-Lopez; Maiken Cavling Arendrup; Cornelia Lass-Floerl; Juan-Luis Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

3.  Development of a UC781 releasing polyethylene vinyl acetate vaginal ring.

Authors:  Christopher McConville; Ian Major; David R Friend; Meredith R Clark; R Karl Malcolm
Journal:  Drug Deliv Transl Res       Date:  2012-12       Impact factor: 4.617

4.  Use of Polyvinyl Alcohol as a Solubility-Enhancing Polymer for Poorly Water Soluble Drug Delivery (Part 1).

Authors:  Chris Brough; Dave A Miller; Justin M Keen; Shawn A Kucera; Dieter Lubda; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2015-12-04       Impact factor: 3.246

5.  Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodology.

Authors:  Ashwini Madgulkar; Shivajirao Kadam; Varsha Pokharkar
Journal:  AAPS PharmSciTech       Date:  2008-09-03       Impact factor: 3.246

6.  Improvement of dissolution behavior for poorly water-soluble drug by application of cyclodextrin in extrusion process: comparison between melt extrusion and wet extrusion.

Authors:  Hideki Yano; Peter Kleinebudde
Journal:  AAPS PharmSciTech       Date:  2010-05-22       Impact factor: 3.246

Review 7.  Quality-by-design in hot melt extrusion based amorphous solid dispersions: An industrial perspective on product development.

Authors:  Arun Butreddy; Suresh Bandari; Michael A Repka
Journal:  Eur J Pharm Sci       Date:  2020-11-28       Impact factor: 4.384

8.  A review of hot-melt extrusion: process technology to pharmaceutical products.

Authors:  Mohammed Maniruzzaman; Joshua S Boateng; Martin J Snowden; Dennis Douroumis
Journal:  ISRN Pharm       Date:  2012-12-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.